Does the media prefer IRD or PURR?

In the previous week, Opus Genetics and Opus Genetics both had 4 articles in the media. Opus Genetics' average media sentiment score of 0.58 beat Hyperliquid Strategies' score of 0.38 indicating that Opus Genetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Opus Genetics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Hyperliquid Strategies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings & valuation, IRD or AKTS?

Opus Genetics has higher revenue and earnings than Aktis Oncology. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Opus Genetics $14.20M 23.61 -$49.59M -$1.33 N/A Aktis Oncology $8.28M 194.28 -$63.73M N/A N/A

Does the media prefer IRD or AKTS?

In the previous week, Opus Genetics and Opus Genetics both had 4 articles in the media. Aktis Oncology's average media sentiment score of 0.62 beat Opus Genetics' score of 0.58 indicating that Aktis Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Opus Genetics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aktis Oncology 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is IMTX or IRD more profitable?

Immatics has a net margin of -572.35% compared to Opus Genetics' net margin of -892.36%. Immatics' return on equity of -47.36% beat Opus Genetics' return on equity. Company Net Margins Return on Equity Return on Assets Immatics -572.35% -47.36% -39.35% Opus Genetics -892.36% -338.88% -191.21%

Does the media refer more to IRD or MPLT?

In the previous week, Maplight Therapeutics had 4 more articles in the media than Opus Genetics. MarketBeat recorded 8 mentions for Maplight Therapeutics and 4 mentions for Opus Genetics. Opus Genetics' average media sentiment score of 0.58 beat Maplight Therapeutics' score of 0.41 indicating that Opus Genetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Opus Genetics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Maplight Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to IRD or PAHC?

In the previous week, Opus Genetics had 1 more articles in the media than Phibro Animal Health. MarketBeat recorded 4 mentions for Opus Genetics and 3 mentions for Phibro Animal Health. Phibro Animal Health's average media sentiment score of 1.40 beat Opus Genetics' score of 0.58 indicating that Phibro Animal Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Opus Genetics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Phibro Animal Health 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Opus Genetics (IRD) Competitors

$4.06 +0.06 (+1.50%)

Closing price 06/29/2026 04:00 PM Eastern

Extended Trading

$3.96 -0.09 (-2.34%)

As of 06/29/2026 07:59 PM Eastern

Compare

IRD vs. PURR, AKTS, IMTX, MPLT, and PAHC

Should you buy Opus Genetics stock or one of its competitors? MarketBeat compares Opus Genetics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Opus Genetics include Hyperliquid Strategies (PURR), Aktis Oncology (AKTS), Immatics (IMTX), Maplight Therapeutics (MPLT), and Phibro Animal Health (PAHC). These companies are all part of the "pharmaceutical products" industry.

How does Opus Genetics compare to Hyperliquid Strategies?

Opus Genetics (NASDAQ:IRD) and Hyperliquid Strategies (NASDAQ:PURR) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, dividends, media sentiment and valuation.

Hyperliquid Strategies has lower revenue, but higher earnings than Opus Genetics. Opus Genetics is trading at a lower price-to-earnings ratio than Hyperliquid Strategies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Opus Genetics	$14.20M	23.61	-$49.59M	-$1.33	N/A
Hyperliquid Strategies	$1M	1,223.49	-$16.01M	-$7.37	N/A

Opus Genetics has a beta of 0.56, indicating that its stock price is 44% less volatile than the broader market. Comparatively, Hyperliquid Strategies has a beta of 1.64, indicating that its stock price is 64% more volatile than the broader market.

15.0% of Opus Genetics shares are owned by institutional investors. Comparatively, 9.5% of Hyperliquid Strategies shares are owned by institutional investors. 11.7% of Opus Genetics shares are owned by company insiders. Comparatively, 8.5% of Hyperliquid Strategies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Opus Genetics and Opus Genetics both had 4 articles in the media. Opus Genetics' average media sentiment score of 0.58 beat Hyperliquid Strategies' score of 0.38 indicating that Opus Genetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Opus Genetics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Hyperliquid Strategies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Opus Genetics currently has a consensus target price of $10.77, indicating a potential upside of 165.25%. Hyperliquid Strategies has a consensus target price of $9.25, indicating a potential upside of 9.21%. Given Opus Genetics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Opus Genetics is more favorable than Hyperliquid Strategies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Opus Genetics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.94
Hyperliquid Strategies	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Hyperliquid Strategies has a net margin of 0.00% compared to Opus Genetics' net margin of -892.36%. Hyperliquid Strategies' return on equity of -56.04% beat Opus Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Opus Genetics	-892.36%	-338.88%	-191.21%
Hyperliquid Strategies	N/A	-56.04%	-52.22%

Summary

Opus Genetics beats Hyperliquid Strategies on 9 of the 16 factors compared between the two stocks.

How does Opus Genetics compare to Aktis Oncology?

Opus Genetics (NASDAQ:IRD) and Aktis Oncology (NASDAQ:AKTS) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and valuation.

15.0% of Opus Genetics shares are held by institutional investors. Comparatively, 28.8% of Aktis Oncology shares are held by institutional investors. 11.7% of Opus Genetics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Aktis Oncology has a net margin of 0.00% compared to Opus Genetics' net margin of -892.36%. Aktis Oncology's return on equity of 0.00% beat Opus Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Opus Genetics	-892.36%	-338.88%	-191.21%
Aktis Oncology	N/A	N/A	N/A

Opus Genetics currently has a consensus price target of $10.77, suggesting a potential upside of 165.25%. Aktis Oncology has a consensus price target of $34.00, suggesting a potential upside of 12.92%. Given Opus Genetics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Opus Genetics is more favorable than Aktis Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Opus Genetics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.94
Aktis Oncology	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

In the previous week, Opus Genetics and Opus Genetics both had 4 articles in the media. Aktis Oncology's average media sentiment score of 0.62 beat Opus Genetics' score of 0.58 indicating that Aktis Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Opus Genetics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aktis Oncology	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Opus Genetics has higher revenue and earnings than Aktis Oncology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Opus Genetics	$14.20M	23.61	-$49.59M	-$1.33	N/A
Aktis Oncology	$8.28M	194.28	-$63.73M	N/A	N/A

Summary

Opus Genetics beats Aktis Oncology on 7 of the 13 factors compared between the two stocks.

How does Opus Genetics compare to Immatics?

Immatics (NASDAQ:IMTX) and Opus Genetics (NASDAQ:IRD) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, risk and profitability.

64.4% of Immatics shares are held by institutional investors. Comparatively, 15.0% of Opus Genetics shares are held by institutional investors. 11.7% of Opus Genetics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Opus Genetics has lower revenue, but higher earnings than Immatics. Immatics is trading at a lower price-to-earnings ratio than Opus Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immatics	$37.30M	34.37	-$222.26M	-$1.99	N/A
Opus Genetics	$14.20M	23.61	-$49.59M	-$1.33	N/A

Immatics has a net margin of -572.35% compared to Opus Genetics' net margin of -892.36%. Immatics' return on equity of -47.36% beat Opus Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immatics	-572.35%	-47.36%	-39.35%
Opus Genetics	-892.36%	-338.88%	-191.21%

Immatics presently has a consensus target price of $20.80, suggesting a potential upside of 117.57%. Opus Genetics has a consensus target price of $10.77, suggesting a potential upside of 165.25%. Given Opus Genetics' stronger consensus rating and higher possible upside, analysts plainly believe Opus Genetics is more favorable than Immatics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immatics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Opus Genetics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.94

Immatics has a beta of 1.3, meaning that its stock price is 30% more volatile than the broader market. Comparatively, Opus Genetics has a beta of 0.56, meaning that its stock price is 44% less volatile than the broader market.

In the previous week, Opus Genetics had 3 more articles in the media than Immatics. MarketBeat recorded 4 mentions for Opus Genetics and 1 mentions for Immatics. Immatics' average media sentiment score of 1.87 beat Opus Genetics' score of 0.58 indicating that Immatics is being referred to more favorably in the media.

Company	Overall Sentiment
Immatics	Very Positive
Opus Genetics	Positive

Summary

Opus Genetics beats Immatics on 9 of the 17 factors compared between the two stocks.

How does Opus Genetics compare to Maplight Therapeutics?

Opus Genetics (NASDAQ:IRD) and Maplight Therapeutics (NASDAQ:MPLT) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, valuation, profitability, earnings, dividends and risk.

Opus Genetics presently has a consensus price target of $10.77, indicating a potential upside of 165.25%. Maplight Therapeutics has a consensus price target of $38.80, indicating a potential upside of 13.12%. Given Opus Genetics' higher probable upside, research analysts clearly believe Opus Genetics is more favorable than Maplight Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Opus Genetics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.94
Maplight Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	4 Strong Buy rating(s)	3.07

Opus Genetics has higher revenue and earnings than Maplight Therapeutics. Opus Genetics is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Opus Genetics	$14.20M	23.61	-$49.59M	-$1.33	N/A
Maplight Therapeutics	N/A	N/A	-$161.15M	-$40.99	N/A

Maplight Therapeutics has a net margin of 0.00% compared to Opus Genetics' net margin of -892.36%. Maplight Therapeutics' return on equity of 0.00% beat Opus Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Opus Genetics	-892.36%	-338.88%	-191.21%
Maplight Therapeutics	N/A	N/A	N/A

15.0% of Opus Genetics shares are owned by institutional investors. 11.7% of Opus Genetics shares are owned by insiders. Comparatively, 3.8% of Maplight Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Maplight Therapeutics had 4 more articles in the media than Opus Genetics. MarketBeat recorded 8 mentions for Maplight Therapeutics and 4 mentions for Opus Genetics. Opus Genetics' average media sentiment score of 0.58 beat Maplight Therapeutics' score of 0.41 indicating that Opus Genetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Opus Genetics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Maplight Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Opus Genetics beats Maplight Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Opus Genetics compare to Phibro Animal Health?

Opus Genetics (NASDAQ:IRD) and Phibro Animal Health (NASDAQ:PAHC) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, media sentiment, institutional ownership, risk, valuation, dividends and profitability.

15.0% of Opus Genetics shares are held by institutional investors. Comparatively, 99.3% of Phibro Animal Health shares are held by institutional investors. 11.7% of Opus Genetics shares are held by company insiders. Comparatively, 50.1% of Phibro Animal Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Opus Genetics has a beta of 0.56, meaning that its share price is 44% less volatile than the broader market. Comparatively, Phibro Animal Health has a beta of 0.47, meaning that its share price is 53% less volatile than the broader market.

Phibro Animal Health has a net margin of 6.35% compared to Opus Genetics' net margin of -892.36%. Phibro Animal Health's return on equity of 37.14% beat Opus Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Opus Genetics	-892.36%	-338.88%	-191.21%
Phibro Animal Health	6.35%	37.14%	8.57%

Phibro Animal Health has higher revenue and earnings than Opus Genetics. Opus Genetics is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Opus Genetics	$14.20M	23.61	-$49.59M	-$1.33	N/A
Phibro Animal Health	$1.30B	1.00	$48.26M	$2.33	13.65

Opus Genetics presently has a consensus target price of $10.77, suggesting a potential upside of 165.25%. Phibro Animal Health has a consensus target price of $42.50, suggesting a potential upside of 33.61%. Given Opus Genetics' stronger consensus rating and higher probable upside, research analysts clearly believe Opus Genetics is more favorable than Phibro Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Opus Genetics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.94
Phibro Animal Health	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Opus Genetics had 1 more articles in the media than Phibro Animal Health. MarketBeat recorded 4 mentions for Opus Genetics and 3 mentions for Phibro Animal Health. Phibro Animal Health's average media sentiment score of 1.40 beat Opus Genetics' score of 0.58 indicating that Phibro Animal Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Opus Genetics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Phibro Animal Health	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Phibro Animal Health beats Opus Genetics on 10 of the 17 factors compared between the two stocks.

Get Opus Genetics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IRD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IRD vs. The Competition

Export

Metric	Opus Genetics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$330.26M	$3.62B	$6.85B	$12.20B
Dividend Yield	N/A	2.21%	2.66%	6.22%
P/E Ratio	-3.05	20.93	26.02	24.36
Price / Sales	23.61	345.52	549.85	102.46
Price / Cash	N/A	62.10	29.09	36.93
Price / Book	18.45	8.71	10.98	6.49
Net Income	-$49.59M	$23.87M	$3.57B	$336.61M
7 Day Performance	-0.49%	3.59%	2.60%	1.25%
1 Month Performance	-6.80%	1.73%	0.93%	0.24%
1 Year Performance	330.95%	69.03%	36.40%	30.16%

Opus Genetics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IRD Opus Genetics	2.9027 of 5 stars	$4.06 +1.5%	$10.77 +165.3%	+315.7%	$330.26M	$14.20M	N/A	14
PURR Hyperliquid Strategies	1.653 of 5 stars	$8.14 -11.5%	$9.25 +13.6%	N/A	$1.33B	$1M	N/A	N/A	Short Interest Increase Gap Down
AKTS Aktis Oncology	1.2941 of 5 stars	$27.01 +9.0%	$34.00 +25.9%	N/A	$1.32B	$8.28M	N/A	76
IMTX Immatics	2.7429 of 5 stars	$9.93 +1.5%	$20.80 +109.5%	+76.1%	$1.31B	$54.60M	N/A	260
MPLT Maplight Therapeutics	2.7826 of 5 stars	$28.64 -3.9%	$38.00 +32.7%	N/A	$1.27B	N/A	N/A	109

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IRD) was last updated on 6/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Opus Genetics (IRD) Competitors

IRD vs. PURR, AKTS, IMTX, MPLT, and PAHC

How does Opus Genetics compare to Hyperliquid Strategies?

Summary

How does Opus Genetics compare to Aktis Oncology?

Summary

How does Opus Genetics compare to Immatics?

Summary

How does Opus Genetics compare to Maplight Therapeutics?

Summary

How does Opus Genetics compare to Phibro Animal Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IRD vs. The Competition

Opus Genetics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Opus Genetics (IRD) Competitors

IRD vs. PURR, AKTS, IMTX, MPLT, and PAHC

How does Opus Genetics compare to Hyperliquid Strategies?

Which has better earnings and valuation, IRD or PURR?

Which has more risk and volatility, IRD or PURR?

Do institutionals & insiders believe in IRD or PURR?

Does the media prefer IRD or PURR?

Do analysts rate IRD or PURR?

Is IRD or PURR more profitable?

Summary

How does Opus Genetics compare to Aktis Oncology?

Do insiders & institutionals believe in IRD or AKTS?

Is IRD or AKTS more profitable?

Do analysts recommend IRD or AKTS?

Does the media prefer IRD or AKTS?

Which has better earnings & valuation, IRD or AKTS?

Summary

How does Opus Genetics compare to Immatics?

Do insiders and institutionals believe in IMTX or IRD?

Which has better valuation and earnings, IMTX or IRD?

Is IMTX or IRD more profitable?

Do analysts rate IMTX or IRD?

Which has more volatility & risk, IMTX or IRD?

Does the media refer more to IMTX or IRD?

Summary

How does Opus Genetics compare to Maplight Therapeutics?

Do analysts prefer IRD or MPLT?

Which has preferable valuation and earnings, IRD or MPLT?

Is IRD or MPLT more profitable?

Do institutionals & insiders believe in IRD or MPLT?

Does the media refer more to IRD or MPLT?

Summary

How does Opus Genetics compare to Phibro Animal Health?

Do institutionals and insiders believe in IRD or PAHC?

Which has more volatility and risk, IRD or PAHC?

Is IRD or PAHC more profitable?

Which has preferable earnings and valuation, IRD or PAHC?

Do analysts rate IRD or PAHC?

Does the media refer more to IRD or PAHC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IRD vs. The Competition

Opus Genetics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools